메뉴 건너뛰기




Volumn 27, Issue 1, 1999, Pages 8-13

Synthetic oligonucleotides: The development of antisense therapeutics

Author keywords

Antisense; Phosphorothioate oligonucleotides

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGONUCLEOTIDE;

EID: 0033052318     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339902700103     Document Type: Conference Paper
Times cited : (66)

References (40)
  • 2
    • 0029791763 scopus 로고    scopus 로고
    • Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal transduction inhibitors
    • Altmann KH, Fabbro D, Dean NM, Geiger T, Monia BP, Muuler M, and Nicklin P (1996). Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal transduction inhibitors. Biochem. Soc. Trans. 24: 630-637.
    • (1996) Biochem. Soc. Trans. , vol.24 , pp. 630-637
    • Altmann, K.H.1    Fabbro, D.2    Dean, N.M.3    Geiger, T.4    Monia, B.P.5    Muuler, M.6    Nicklin, P.7
  • 3
    • 0031912506 scopus 로고    scopus 로고
    • Antisense oligonucleotides: Is the glass half full or half empty?
    • Bennett CF (1998). Antisense oligonucleotides: Is the glass half full or half empty? Biochem. Pharmacol. 55: 9-19.
    • (1998) Biochem. Pharmacol. , vol.55 , pp. 9-19
    • Bennett, C.F.1
  • 5
    • 0030222182 scopus 로고    scopus 로고
    • Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid
    • Bennett CF, Zuckerman JE, Kornbrust D, Sasmor H, Leeds JM, and Crooke ST (1996). Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid. J. Controlled Release 41: 121-130.
    • (1996) J. Controlled Release , vol.41 , pp. 121-130
    • Bennett, C.F.1    Zuckerman, J.E.2    Kornbrust, D.3    Sasmor, H.4    Leeds, J.M.5    Crooke, S.T.6
  • 6
    • 0027481659 scopus 로고
    • Progress toward oligonucleotide therapeutics: Pharmacodynamic properties
    • Crooke ST (1993). Progress toward oligonucleotide therapeutics: Pharmacodynamic properties. FASEB 7: 533-539.
    • (1993) FASEB , vol.7 , pp. 533-539
    • Crooke, S.T.1
  • 7
    • 0001675653 scopus 로고
    • Oligonucleotide therapeutics
    • 5th ed., ME Wolff (ed). Wiley and Sons, New York
    • Crooke ST (1995). Oligonucleotide therapeutics. In: Burger's Medicinal Chemistry and Drug Discovery, Vol. 1, 5th ed., ME Wolff (ed). Wiley and Sons, New York, pp. 863-900.
    • (1995) Burger's Medicinal Chemistry and Drug Discovery , vol.1 , pp. 863-900
    • Crooke, S.T.1
  • 9
    • 0030839546 scopus 로고    scopus 로고
    • Identification and characterization of second-generation antisense oligonucleotides
    • Dean NM and Griffey RH (1997). Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 7: 229-233.
    • (1997) Antisense Nucleic Acid Drug Dev. , vol.7 , pp. 229-233
    • Dean, N.M.1    Griffey, R.H.2
  • 10
    • 0028062847 scopus 로고
    • Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides
    • Dean NM and McKay R (1994). Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 91: 11762-11766.
    • (1994) Proc. Natl. Acad. Sci. USA , vol.91 , pp. 11762-11766
    • Dean, N.M.1    McKay, R.2
  • 11
    • 0015150973 scopus 로고
    • Stimulation of humoral antibody formation by polyanions. II. The influence of sulfate esters of polymers on the immune response in mice
    • Diamantstein T, Wagner B, Beyse I, Odenwald MV, and Schultz G (1971). Stimulation of humoral antibody formation by polyanions. II. The influence of sulfate esters of polymers on the immune response in mice. Eur. J. Immunol. 1: 340-343.
    • (1971) Eur. J. Immunol. , vol.1 , pp. 340-343
    • Diamantstein, T.1    Wagner, B.2    Beyse, I.3    Odenwald, M.V.4    Schultz, G.5
  • 12
    • 0028596461 scopus 로고
    • Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey
    • Galbraith WM, Hobson WC, Giclas PC, Schlechter PJ, and Agrawal S (1994). Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4: 201-206.
    • (1994) Antisense Res. Dev. , vol.4 , pp. 201-206
    • Galbraith, W.M.1    Hobson, W.C.2    Giclas, P.C.3    Schlechter, P.J.4    Agrawal, S.5
  • 13
    • 0030667690 scopus 로고    scopus 로고
    • Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression
    • Geary RS, Leeds JM, Fitchett J, Burckin T, Troung L, Spainhour C, Creek M, and Levin AA (1997). Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos. 25: 1272-1281.
    • (1997) Drug Metab. Dispos. , vol.25 , pp. 1272-1281
    • Geary, R.S.1    Leeds, J.M.2    Fitchett, J.3    Burckin, T.4    Troung, L.5    Spainhour, C.6    Creek, M.7    Levin, A.A.8
  • 14
    • 0030797704 scopus 로고    scopus 로고
    • Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides
    • Geary RS, Leeds JM, Henry SP, Monteith DM, and Levin AA (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des. 12: 383-394.
    • (1997) Anti-Cancer Drug Des. , vol.12 , pp. 383-394
    • Geary, R.S.1    Leeds, J.M.2    Henry, S.P.3    Monteith, D.M.4    Levin, A.A.5
  • 16
    • 0030918233 scopus 로고    scopus 로고
    • Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys
    • Henry SP, Bolte H, Auletta C, and Kornbrust DJ (1997). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology 120: 145-155.
    • (1997) Toxicology , vol.120 , pp. 145-155
    • Henry, S.P.1    Bolte, H.2    Auletta, C.3    Kornbrust, D.J.4
  • 17
  • 18
    • 0031036843 scopus 로고    scopus 로고
    • Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats
    • Henry SP, Grillone LR, Orr JL, Brunner RH, and Kornbrust DJ (1997). Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats. Toxicology 116: 77-88.
    • (1997) Toxicology , vol.116 , pp. 77-88
    • Henry, S.P.1    Grillone, L.R.2    Orr, J.L.3    Brunner, R.H.4    Kornbrust, D.J.5
  • 19
    • 0030860587 scopus 로고    scopus 로고
    • Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicologic properties of phosphorothioate oligodeoxynucleotides
    • Henry SP, Monteith D, and Levin AA (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicologic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des. 12: 395-408.
    • (1997) Anti-Cancer Drug Des. , vol.12 , pp. 395-408
    • Henry, S.P.1    Monteith, D.2    Levin, A.A.3
  • 21
    • 0030806664 scopus 로고    scopus 로고
    • Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice
    • Henry SP, Taylor J, Midgley L, Levin AA, and Kornbrust DJ (1997). Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev. 7: 473-481.
    • (1997) Antisense Nucleic Acid Drug Dev. , vol.7 , pp. 473-481
    • Henry, S.P.1    Taylor, J.2    Midgley, L.3    Levin, A.A.4    Kornbrust, D.J.5
  • 26
    • 0029933947 scopus 로고    scopus 로고
    • Recent status of the antisense oligonucleotide approaches in oncology
    • Ma L and Calvo F (1996). Recent status of the antisense oligonucleotide approaches in oncology. Fundam. Clin. Pharmacol. 10: 97-115.
    • (1996) Fundam. Clin. Pharmacol. , vol.10 , pp. 97-115
    • Ma, L.1    Calvo, F.2
  • 30
  • 31
    • 0032430114 scopus 로고    scopus 로고
    • Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys
    • in press
    • Monteith DK, Geary RS, Leeds JM, Johnston J, Monia BP, and Levin AA (1998). Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol. Sci. 46: (in press).
    • (1998) Toxicol. Sci. , vol.46
    • Monteith, D.K.1    Geary, R.S.2    Leeds, J.M.3    Johnston, J.4    Monia, B.P.5    Levin, A.A.6
  • 33
    • 0030776403 scopus 로고    scopus 로고
    • Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration
    • Phillips JA, Craig SJ, Bayley D, Christian RA, Geary R, and Nicklin PL (1997). Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol. 54: 657-668.
    • (1997) Biochem. Pharmacol. , vol.54 , pp. 657-668
    • Phillips, J.A.1    Craig, S.J.2    Bayley, D.3    Christian, R.A.4    Geary, R.5    Nicklin, P.L.6
  • 34
    • 0027954331 scopus 로고
    • Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus
    • Pisetsky DS and Reich CF (1994). Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci. 54: 101-107.
    • (1994) Life Sci. , vol.54 , pp. 101-107
    • Pisetsky, D.S.1    Reich, C.F.2
  • 35
    • 0027933160 scopus 로고
    • In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice
    • Sarmiento UM, Perez JR, Becker JM, and Ramaswamy N (1994). In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev. 4: 99-107.
    • (1994) Antisense Res. Dev. , vol.4 , pp. 99-107
    • Sarmiento, U.M.1    Perez, J.R.2    Becker, J.M.3    Ramaswamy, N.4
  • 36
    • 0022544031 scopus 로고
    • In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG
    • Shimada S, Yano O, and Tokunaga T (1986). In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG. Jpn. J. Cancer Res. 77: 808-816.
    • (1986) Jpn. J. Cancer Res. , vol.77 , pp. 808-816
    • Shimada, S.1    Yano, O.2    Tokunaga, T.3
  • 37
    • 0027987972 scopus 로고
    • Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities
    • Stepkowski SM, Tu Y, Condon TP, and Bennett CF (1994). Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J. Immunol. 153: 5336-5346.
    • (1994) J. Immunol. , vol.153 , pp. 5336-5346
    • Stepkowski, S.M.1    Tu, Y.2    Condon, T.P.3    Bennett, C.F.4
  • 38
    • 0023683638 scopus 로고
    • A synthetic single-stranded DNA, poly (dG, dC), induces interferon-α/β and -γ augments natural killer activity, and suppresses tumor growth
    • Tokunaga T, Yamamato S, and Namba K (1988). A synthetic single-stranded DNA, poly (dG, dC), induces interferon-α/β and -γ augments natural killer activity, and suppresses tumor growth. Jpn. J. Cancer Res. 79: 682-686.
    • (1988) Jpn. J. Cancer Res. , vol.79 , pp. 682-686
    • Tokunaga, T.1    Yamamato, S.2    Namba, K.3
  • 39
    • 0028087886 scopus 로고
    • Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length
    • Yamamoto T, Yamamoto S, Kataoka T, and Tokunaga T (1994). Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res. Dev. 4: 119-122.
    • (1994) Antisense Res. Dev. , vol.4 , pp. 119-122
    • Yamamoto, T.1    Yamamoto, S.2    Kataoka, T.3    Tokunaga, T.4
  • 40
    • 0029833019 scopus 로고    scopus 로고
    • Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide
    • Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL and Glazer RI (1996). Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol. Pharmacol. 50: 236-242.
    • (1996) Mol. Pharmacol. , vol.50 , pp. 236-242
    • Yazaki, T.1    Ahmad, S.2    Chahlavi, A.3    Zylber-Katz, E.4    Dean, N.M.5    Rabkin, S.D.6    Martuza, R.L.7    Glazer, R.I.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.